1
|
Monieri M, Rainone P, Sacchi A, Gori A, Gasparri AM, Coliva A, Citro A, Ferrara B, Policardi M, Valtorta S, Pocaterra A, Alfano M, Sheppard D, Piemonti L, Moresco RM, Corti A, Curnis F. A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins. Int J Biol Sci 2023; 19:156-166. [PMID: 36594095 PMCID: PMC9760430 DOI: 10.7150/ijbs.76148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 09/15/2022] [Indexed: 11/24/2022] Open
Abstract
Rationale: The αvβ6- and αvβ8-integrins, two cell-adhesion receptors upregulated in many tumors and involved in the activation of the latency associated peptide (LAP)/TGFβ complex, represent potential targets for tumor imaging and therapy. We investigated the tumor-homing properties of a chromogranin A-derived peptide containing an RGDL motif followed by a chemically stapled alpha-helix (called "5a"), which selectively recognizes the LAP/TGFβ complex-binding site of αvβ6 and αvβ8. Methods: Peptide 5a was labeled with IRDye 800CW (a near-infrared fluorescent dye) or with 18F-NOTA (a label for positron emission tomography (PET)); the integrin-binding properties of free peptide and conjugates were then investigated using purified αvβ6/αvβ8 integrins and various αvβ6/αvβ8 single - or double-positive cancer cells; tumor-homing, biodistribution and imaging properties of the conjugates were investigated in subcutaneous and orthotopic αvβ6-positive carcinomas of the pancreas, and in mice bearing subcutaneous αvβ8-positive prostate tumors. Results: In vitro studies showed that 5a can bind both integrins with high affinity and inhibits cell-mediated TGFβ activation. The 5a-IRDye and 5a-NOTA conjugates could bind purified αvβ6/αvβ8 integrins with no loss of affinity compared to free peptide, and selectively recognized various αvβ6/αvβ8 single- or double-positive cancer cells, including cells from pancreatic carcinoma, melanoma, oral mucosa, bladder and prostate cancer. In vivo static and dynamic optical near-infrared and PET/CT imaging and biodistribution studies, performed in mice with subcutaneous and orthotopic αvβ6-positive carcinomas of the pancreas, showed high target-specific uptake of fluorescence- and radio-labeled peptide by tumors and low non-specific uptake in other organs and tissues, except for excretory organs. Significant target-specific uptake of fluorescence-labeled peptide was also observed in mice bearing αvβ8-positive prostate tumors. Conclusions: The results indicate that 5a can home to αvβ6- and/or αvβ8-positive tumors, suggesting that this peptide can be exploited as a ligand for delivering imaging or anticancer agents to αvβ6/αvβ8 single- or double-positive tumors, or as a tumor-homing inhibitor of these TGFβ activators.
Collapse
Affiliation(s)
- Matteo Monieri
- Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Paolo Rainone
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.,Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Angelina Sacchi
- Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alessandro Gori
- Istituto di Scienze e Tecnologie Chimiche, C.N.R., Milan, Italy
| | - Anna Maria Gasparri
- Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Angela Coliva
- Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Antonio Citro
- Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Benedetta Ferrara
- Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Martina Policardi
- Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Silvia Valtorta
- Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.,Institute of Molecular Bioimaging and Physiology of C.N.R., Segrate, Italy
| | - Arianna Pocaterra
- Division of Immunology Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Massimo Alfano
- Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Dean Sheppard
- Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Lorenzo Piemonti
- Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.,Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy
| | - Rosa Maria Moresco
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.,Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.,Institute of Molecular Bioimaging and Physiology of C.N.R., Segrate, Italy
| | - Angelo Corti
- Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.,Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.,✉ Corresponding authors: Angelo Corti (ORICD: 0000-0002-0893-6191) and Flavio Curnis (ORICD: 0000-0002-7231-9569), Division of Experimental Oncology, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy (Tel. +390226434802; E-mail: and )
| | - Flavio Curnis
- Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.,✉ Corresponding authors: Angelo Corti (ORICD: 0000-0002-0893-6191) and Flavio Curnis (ORICD: 0000-0002-7231-9569), Division of Experimental Oncology, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy (Tel. +390226434802; E-mail: and )
| |
Collapse
|
2
|
Alchera E, Monieri M, Maturi M, Locatelli I, Locatelli E, Tortorella S, Sacchi A, Corti A, Nebuloni M, Lucianò R, Pederzoli F, Montorsi F, Salonia A, Meyer S, Jose J, Giustetto P, Franchini MC, Curnis F, Alfano M. Early diagnosis of bladder cancer by photoacoustic imaging of tumor-targeted gold nanorods. Photoacoustics 2022; 28:100400. [PMID: 36386292 PMCID: PMC9649962 DOI: 10.1016/j.pacs.2022.100400] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 06/30/2022] [Accepted: 08/29/2022] [Indexed: 06/16/2023]
Abstract
Detection and removal of bladder cancer lesions at an early stage is crucial for preventing tumor relapse and progression. This study aimed to develop a new technological platform for the visualization of small and flat urothelial lesions of high-grade bladder carcinoma in situ (CIS). We found that the integrin α5β1, overexpressed in bladder cancer cell lines, murine orthotopic bladder cancer and human bladder CIS, can be exploited as a receptor for targeted delivery of GNRs functionalized with the cyclic CphgisoDGRG peptide (Iso4). The GNRs@Chit-Iso4 was stable in urine and selectively recognized α5β1 positive neoplastic urothelium, while low frequency ultrasound-assisted shaking of intravesically instilled GNRs@Chit-Iso4 allowed the distribution of nanoparticles across the entire volume of the bladder. Photoacoustic imaging of GNRs@Chit-Iso4 bound to tumor cells allowed for the detection of neoplastic lesions smaller than 0.5 mm that were undetectable by ultrasound imaging and bioluminescence.
Collapse
Affiliation(s)
- Elisa Alchera
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Matteo Monieri
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Mirko Maturi
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Irene Locatelli
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Erica Locatelli
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Silvia Tortorella
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Angelina Sacchi
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Angelo Corti
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Manuela Nebuloni
- Pathology Unit, Department of Biomedical and Clinical Sciences, L. Sacco Hospital, Università degli Studi di Milano, Milan, Italy
| | - Roberta Lucianò
- Department of Pathology, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy
| | - Filippo Pederzoli
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Francesco Montorsi
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Andrea Salonia
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
- Università Vita-Salute San Raffaele, Milan, Italy
| | - Sandra Meyer
- FUJIFILM Visualsonics Inc., Amsterdam, the Netherlands
| | - Jithin Jose
- FUJIFILM Visualsonics Inc., Amsterdam, the Netherlands
| | | | - Mauro Comes Franchini
- Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy
| | - Flavio Curnis
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Massimo Alfano
- Unit of Urology, URI, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
3
|
Sacchi A, Gasparri AM, Monieri M, Anderluzzi G, Colombo B, Gori A, Corti A, Curnis F. Nanogold Functionalized With Lipoamide- isoDGR: A Simple, Robust and Versatile Nanosystem for αvβ3-Integrin Targeting. Front Chem 2021; 9:690357. [PMID: 34124009 PMCID: PMC8194705 DOI: 10.3389/fchem.2021.690357] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Accepted: 05/17/2021] [Indexed: 11/13/2022] Open
Abstract
Gold nanoparticles functionalized with isoDGR, a tripeptide motif that recognizes αvβ3 integrin overexpressed in tumor vessels, have been used as nano-vectors for the delivery of cytokines to tumors. Functionalization of nanogold with this peptide has been achieved by coating nanoparticles with a peptide-albumin conjugate consisting of heterogeneous molecules with a variable number of linkers and peptides. To reduce nanodrug heterogeneity we have designed, produced and preclinically evaluated a homogeneous and well-defined reagent for nanogold functionalization, consisting of a head-to-tail cyclized CGisoDGRG peptide (iso1) coupled via its thiol group to maleimide-PEG11-lipoamide (LPA). The resulting iso1-PEG11-LPA compound can react with nanogold via lipoamide to form a stable bond. In vitro studies have shown that iso1, after coupling to nanogold, maintains its capability to bind purified αvβ3 and αvβ3-expressing cells. Nanogold functionalized with this peptide can also be loaded with bioactive tumor necrosis factor-α (TNF) to form a bi-functional nanodrug that can be stored for three days at 37°C or >1 year at low temperatures with no loss αvβ3-binding properties and TNF-cytolytic activity. Nanoparticles functionalized with both iso1 and TNF induced tumor eradication in WEHI-164 fibrosarcoma-bearing mice more efficiently than nanoparticles lacking the iso1 targeting moiety. These results suggest that iso1-PEG11-LPA is an efficient and well-defined reagent that can be used to produce robust and more homogeneous nano-vectors for the delivery of TNF and other cytokines to αvβ3 positive cells.
Collapse
Affiliation(s)
- Angelina Sacchi
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Anna Maria Gasparri
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | | | | | - Barbara Colombo
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Alessandro Gori
- Istituto di Scienze e Tecnologie Chimiche, C.N.R., Milan, Italy
| | - Angelo Corti
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.,Università Vita-Salute San Raffaele, Milan, Italy
| | - Flavio Curnis
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| |
Collapse
|
4
|
Corti A, Sacchi A, Gasparri AM, Monieri M, Anderluzzi G, Colombo B, Gori A, Mondino A, Curnis F. Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold. J Nanobiotechnology 2021; 19:128. [PMID: 33952242 PMCID: PMC8097910 DOI: 10.1186/s12951-021-00871-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Accepted: 04/24/2021] [Indexed: 12/15/2022] Open
Abstract
Background Gold nanospheres tagged with peptides containing isoDGR (isoAsp-Gly-Arg), an αvβ3 integrin binding motif, represent efficient carriers for delivering pro-inflammatory cytokines to the tumor vasculature. We prepared bi- or trifunctional nanoparticles bearing tumor necrosis factor-α (TNF) and/or interleukin-12 (IL12) plus a peptide containing isoDGR, and we tested their anti-cancer effects, alone or in combination with doxorubicin, in tumor-bearing mice. Results In vitro biochemical studies showed that both nanodrugs were monodispersed and functional in terms of binding to TNF and IL12 receptors and to αvβ3. In vivo studies performed in a murine model of fibrosarcoma showed that low doses of bifunctional nanoparticles bearing isoDGR and TNF (corresponding to few nanoparticles per cell) delayed tumor growth and increased the efficacy of doxorubicin without worsening its toxicity. Similar effects were obtained using trifunctional nanoparticles loaded with isoDGR, TNF and IL12. Mechanistic studies showed that nanoparticles bearing isoDGR and TNF could increase doxorubicin penetration in tumors a few hours after injection and caused vascular damage at later time points. Conclusion IsoDGR-coated gold nanospheres can be exploited as a versatile platform for single- or multi-cytokine delivery to cells of the tumor vasculature. Extremely low doses of isoDGR-coated nanodrugs functionalized with TNF or TNF plus IL12 can enhance doxorubicin anti-tumor activity. Graphic Abstract ![]()
Supplementary Information The online version contains supplementary material available at 10.1186/s12951-021-00871-y.
Collapse
Affiliation(s)
- Angelo Corti
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy. .,Università Vita-Salute San Raffaele, Milan, Italy.
| | - Angelina Sacchi
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy
| | - Anna Maria Gasparri
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy
| | | | | | - Barbara Colombo
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy
| | - Alessandro Gori
- Istituto di Scienze e Tecnologie Chimiche, C.N.R., Via Mario Bianco 9, 20131, Milan, Italy
| | - Anna Mondino
- Lymphocyte Activation Unit, Division of Immunology, Transplantation and Infectious Diseases IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Flavio Curnis
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, via Olgettina 58, 20132, Milan, Italy.
| |
Collapse
|
5
|
Truffi M, Sevieri M, Morelli L, Monieri M, Mazzucchelli S, Sorrentino L, Allevi R, Bonizzi A, Zerbi P, Marchini B, Longhi E, Sampietro GM, Colombo F, Prosperi D, Colombo M, Corsi F. Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease. Int J Nanomedicine 2020; 15:8537-8552. [PMID: 33173291 PMCID: PMC7646444 DOI: 10.2147/ijn.s264513] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 09/01/2020] [Indexed: 12/19/2022] Open
Abstract
Purpose Assessment of inflammatory bowel disease (IBD) currently relies on aspecific clinical signs of bowel inflammation. Specific imaging of the diseased bowel regions is still lacking. Here, we investigate mucosal addressin cell adhesion molecule 1 (MAdCAM-1) as a reliable and specific endothelial target for engineered nanoparticles delivering imaging agents to obtain an exact mapping of diseased bowel foci. Materials and Methods We generated a nanodevice composed of PLGA-PEG coupled with anti-MAdCAM-1 antibody half-chains and loaded with quantum dots (P@QD-MdC NPs). Bowel localization and systemic biodistribution of the nanoconjugate were analyzed upon injection in a murine model of chronic IBD obtained through repeated administration of dextran sulfate sodium salt. Specificity for diseased bowel regions was also assessed ex vivo in human specimens from patients with IBD. Potential for development as contrast agent in magnetic resonance imaging was assessed by preliminary study on animal model. Results Synthesized nanoparticles revealed good stability and monodispersity. Molecular targeting properties were analyzed in vitro in a cell culture model. Upon intravenous injection, P@QD-MdC NPs were localized in the bowel of colitic mice, with enhanced accumulation at 24 h post-injection compared to untargeted nanoparticles (p<0.05). Nanoparticles injection did not induce histologic lesions in non-target organs. Ex vivo exposure of human bowel specimens to P@QD-MdC NPs revealed specific recognition of the diseased regions vs uninvolved tracts (p<0.0001). After loading with appropriate contrast agent, the nanoparticles enabled localized contrast enhancement of bowel mucosa in the rectum of treated mice. Conclusion P@QD-MdC NPs efficiently detected bowel inflammation foci, accurately following the expression pattern of MAdCAM-1. Fine-tuning of this nanoconjugate with appropriate imaging agents offers a promising non-invasive tool for specific IBD diagnosis.
Collapse
Affiliation(s)
- Marta Truffi
- Nanomedicine and Molecular Imaging Laboratory, Istituti Clinici Scientifici Maugeri IRCCS, Pavia 27100, Italy
| | - Marta Sevieri
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Lucia Morelli
- NanoBioLab, Department of Biotechnology and Biosciences, Università degli studi di Milano-Bicocca, Milano, 20126, Italy
| | - Matteo Monieri
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Luca Sorrentino
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Raffaele Allevi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Arianna Bonizzi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Pietro Zerbi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Beatrice Marchini
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Erika Longhi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy
| | - Gianluca Matteo Sampietro
- IBD Surgery Unit, ASST Fatebenefratelli Sacco - Ospedale "Luigi Sacco" Polo Universitario, Milano, 20157, Italy
| | - Francesco Colombo
- IBD Surgery Unit, ASST Fatebenefratelli Sacco - Ospedale "Luigi Sacco" Polo Universitario, Milano, 20157, Italy
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnology and Biosciences, Università degli studi di Milano-Bicocca, Milano, 20126, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnology and Biosciences, Università degli studi di Milano-Bicocca, Milano, 20126, Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "Luigi Sacco, Università degli studi di Milano, Milano, 20157, Italy.,Surgery Department, Breast Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, 27100, Italy
| |
Collapse
|
6
|
Corti A, Gasparri AM, Sacchi A, Colombo B, Monieri M, Rrapaj E, Ferreri AJM, Curnis F. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. Mol Pharm 2020; 17:3813-3824. [PMID: 32805112 DOI: 10.1021/acs.molpharmaceut.0c00579] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The therapeutic index of cytokines in cancer therapy can be increased by targeting strategies based on protein engineering with peptides containing the CNGRC (NGR) motif, a ligand that recognizes CD13-positive tumor vessels. We show here that the targeting domain of recombinant CNGRC-cytokine fusion proteins, such as NGR-TNF (a CNGRC-tumor necrosis factor-α (TNF) conjugate used in clinical studies) and NGR-EMAP-II, undergoes various post-translational modification and degradation reactions that lead to the formation of markedly heterogeneous products. These modifications include N-terminal cysteine acetylation or the formation of various asparagine degradation products, the latter owing to intramolecular interactions of the cysteine α-amino group with asparagine and/or its succinimide derivative. Blocking the cysteine α-amino group with a serine (SCNGRC) reduced both post-translational and degradation reactions. Furthermore, the serine residue reduced the asparagine deamidation rate to isoaspartate (another degradation product) and improved the affinity of NGR for CD13. Accordingly, genetic engineering of NGR-TNF with the N-terminal serine produced a more stable and homogeneous drug (called S-NGR-TNF) with improved antitumor activity in tumor-bearing mice, either when used alone or in combination with chemotherapy. In conclusion, the targeting domain of NGR-cytokine conjugates can undergo various untoward modification and degradation reactions, which can be markedly reduced by fusing a serine to the N-terminus. The SCNGRC peptide may represent a ligand for cytokine delivery to tumors more robust than conventional CNGRC. The S-NGR-TNF conjugate (more stable, homogeneous, and active than NGR-TNF) could be rapidly developed for clinical trials.
Collapse
Affiliation(s)
- Angelo Corti
- Università Vita-Salute San Raffaele, Milan 20132, Italy.,Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Anna Maria Gasparri
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Angelina Sacchi
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Barbara Colombo
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Matteo Monieri
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Eltjona Rrapaj
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Andrés J M Ferreri
- Lymphoma Unit, Department of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| | - Flavio Curnis
- Tumor Biology and Vascular Targeting Unit, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
| |
Collapse
|
7
|
Salvioni L, Zuppone S, Andreata F, Monieri M, Mazzucchelli S, Di Carlo C, Morelli L, Cordiglieri C, Donnici L, De Francesco R, Corsi F, Prosperi D, Vago R, Colombo M. Nanoparticle‐Mediated Suicide Gene Therapy for Triple Negative Breast Cancer Treatment. Adv Therap 2020. [DOI: 10.1002/adtp.202000007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Lucia Salvioni
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| | - Stefania Zuppone
- Urologic Research InstituteDivision of Experimental OncologyIRCCS San Raffaele Scientific Institute via Olgettina 60 Milan 20132 Italy
| | - Francesco Andreata
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
| | - Matteo Monieri
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
| | - Serena Mazzucchelli
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
| | - Caterina Di Carlo
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| | - Lucia Morelli
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| | - Chiara Cordiglieri
- INGM – Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Via Francesco Sforza 35 Milan 20122 Italy
| | - Lorena Donnici
- INGM – Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Via Francesco Sforza 35 Milan 20122 Italy
| | - Raffaele De Francesco
- INGM – Istituto Nazionale di Genetica Molecolare “Romeo ed Enrica Invernizzi,” Via Francesco Sforza 35 Milan 20122 Italy
- Department of Pharmacological and Biomolecular Sciences via Balzaretti 9 Milano 20133 Italy
| | - Fabio Corsi
- Nanomedicine LaboratoryDepartment of Biomedical and Clinical Sciences “L. Sacco”Università degli Studi di Milano via G. B. Grassi, 74 Milan 20157 Italy
- Breast UnitSurgery DepartmentICS Maugeri IRCCS via S. Maugeri 10 Pavia 27100 Italy
| | - Davide Prosperi
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
- Breast UnitSurgery DepartmentICS Maugeri IRCCS via S. Maugeri 10 Pavia 27100 Italy
| | - Riccardo Vago
- Urologic Research InstituteDivision of Experimental OncologyIRCCS San Raffaele Scientific Institute via Olgettina 60 Milan 20132 Italy
- Università Vita‐Salute San Raffaele via Olgettina, 58 Milan 20132 Italy
| | - Miriam Colombo
- NanoBioLabDepartment of Biotechnology and BiosciencesUniversity of Milano‐Bicocca Piazza della Scienza 2 Milan 20126 Italy
| |
Collapse
|
8
|
Nardelli F, Ghitti M, Quilici G, Gori A, Luo Q, Berardi A, Sacchi A, Monieri M, Bergamaschi G, Bermel W, Chen F, Corti A, Curnis F, Musco G. A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8. Chem Commun (Camb) 2020; 55:14777-14780. [PMID: 31755501 DOI: 10.1039/c9cc08518a] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Combining 2D STD-NMR, computation, biochemical assays and click-chemistry, we have identified a chromogranin-A derived compound (5) that has high affinity and bi-selectivity for αvβ6 and αvβ8 integrins and is stable in microsomal preparations. 5 is suitable for nanoparticle functionalization and delivery to cancer cells, holding promise for diagnostic and/or therapeutic applications.
Collapse
Affiliation(s)
- Francesca Nardelli
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Michela Ghitti
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Giacomo Quilici
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Alessandro Gori
- Istituto di Chimica del Riconoscimento Molecolare, C.N.R., Via Mario Bianco 9, 20131 Milan, Italy
| | - Qingqiong Luo
- Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China
| | - Andrea Berardi
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Angelina Sacchi
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Matteo Monieri
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Greta Bergamaschi
- Istituto di Chimica del Riconoscimento Molecolare, C.N.R., Via Mario Bianco 9, 20131 Milan, Italy
| | - Wolfgang Bermel
- Bruker BioSpin GmbH, Silberstreifen 4, Rheinstetten, 76287, Germany
| | - Fuxiang Chen
- Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, 639 Zhizaoju Road, Shanghai, 200011, China
| | - Angelo Corti
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy. and Vita Salute San Raffaele University, Via Olgettina 58, 20132 Milan, Italy
| | - Flavio Curnis
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| | - Giovanna Musco
- IRCCS San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy.
| |
Collapse
|
9
|
Mazzucchelli S, Andreata F, Bonizzi A, Monieri M, Bellini M, Longhi E, Ottria R, Sorrentino L, Truffi M, Prosperi D, Zerbi P, Corsi F. Abstract P1-20-04: Nanoformulation of doxorubicin inside H- ferritin nanocages allows a cardio-safe combined therapy with trastuzumab: De-escalating cardiotoxicity in HER2-positive breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-20-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2+ breast cancer (BC) accounts for 20-25 % of BCs and it is characterized by high aggressiveness.1 Despite the anti-HER2 monoclonal antibody Trastuzumab (TZ) has improved BC clinical outcome, it could induce severe cardiac reversible dysfunction:2 HER2 signaling is also essential for growth and survival of myocardiocytes.3 Therefore, the concurrent use of TZ with other cardiotoxic drugs as doxorubicin (DOX) is discouraged.3 Both neoadjuvant and adjuvant clinical trials have challenged the notion that TZ should be administered with anthracyclines only sequentially,4 despite pre-clinical studies demonstrated the significant enhancement of efficacy by their coadministration.5-7 Nanomedicine answers to this clinical issue with HFn-DOX: a natural protein-based DOX nanoformulation with native tumor targeting capability that displays a self-triggered nuclear delivery of DOX improving antitumor efficacy and reducing both chemoresistance and cardiotoxicity.8
Methods: HER2+ BC bearing mice have been treated 5 times twice a week with placebo, HFn-DOX (1 mg/Kg, i.v.), TZ (5 mg/Kg, i.p.) and with the combination of them. Main end-point were cardiotoxicity and anticancer efficacy. Tumor size was measured by caliper, while antitumor activity and cardiotoxicity were characterized by ICH, immunofluorescence, cytofluorimetry, TEM, mass spectrometry and western blot on resections. Statistical analyses were conducted using two-tailed Student's t-test (P< 0.05)
Results: Although single treatments with HFn-DOX or TZ display a good capability to reduce tumor progression, their combination improves antitumor potential, affecting tumor size and angiogenesis. Since the main TZ activity is the induction of the Antibody-Dependent Cell mediated Cytotoxicity, we have assessed the effect of HFn-DOX on Tumor Infiltrating Lymphocytes (TIL), revealing that both TILs enumeration and TIL activity is unaffected by HFn-DOX. On the other hand, HFn-DOX increases the induction of apoptosis, suggesting that the reduction of the tumor size observed in mice treated with the combination of TZ and HFn-DOX is attributable to the coupling of these activity. Mitochondrial morphology has been checked for cardiotoxicity. A pathological increase in mitochondria area coupled with cristae depletion has been evidenced only in mice treated with TZ alone, confirming the overall safety of the HFn-DOX formulation. Interestingly, mice treated with the TZ and HFn-DOX did not display evidences of cardiac suffering. TZ quantification in tumor and heart revealed that the combination with HFn-DOX couples the increased TZ accumulation and penetration in tumor with TZ reduction in heart, resulting in the lack of cardiotoxicity.
Conclusions: Our results suggest that a combined therapy with HFn-DOX and TZ allows an enhanced anticancer activity and reduced cardiotoxicity, with potential translational implications on the treatment of HER2+ BC patients.
[1] Nat Rev Cancer 2009; 9:463; [2] Nat. Med. 2012; 18(11):1639; [3] Cancer treatments reviews 2009; 35:633; [4] The breast 2014; 23:317; [5] Cancer Res. 1998; 58(13):2825; [6] Lancet Oncol. 2011; 12(3):236; [7] Lancet 2010; 375(9712):377. [8] Oncotarget. 2017; 8:8383.
Citation Format: Mazzucchelli S, Andreata F, Bonizzi A, Monieri M, Bellini M, Longhi E, Ottria R, Sorrentino L, Truffi M, Prosperi D, Zerbi P, Corsi F. Nanoformulation of doxorubicin inside H- ferritin nanocages allows a cardio-safe combined therapy with trastuzumab: De-escalating cardiotoxicity in HER2-positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-20-04.
Collapse
Affiliation(s)
- S Mazzucchelli
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - F Andreata
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - A Bonizzi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - M Monieri
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - M Bellini
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - E Longhi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - R Ottria
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - L Sorrentino
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - M Truffi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - D Prosperi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - P Zerbi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| | - F Corsi
- University of Milan, Department of Biomedical and Clinical Sciences "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri Spa SB, Breast Unit, Pavia, Italy
| |
Collapse
|
10
|
Corsi F, Andreata F, Truffi M, Sorrentino L, D'Addio F, Monieri M, Gambaro A, Bellini M, Prosperi D, Mazzucchelli S. Abstract P4-06-09: Withdrawn. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Citation Format: Corsi F, Andreata F, Truffi M, Sorrentino L, D'Addio F, Monieri M, Gambaro A, Bellini M, Prosperi D, Mazzucchelli S. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-09.
Collapse
Affiliation(s)
- F Corsi
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - F Andreata
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - M Truffi
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - L Sorrentino
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - F D'Addio
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - M Monieri
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - A Gambaro
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - M Bellini
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - D Prosperi
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| | - S Mazzucchelli
- University of Milan, Milan, Italy; Breast Unit, ICS Maugeri S.p.A. SB, Pavia, Italy; Clinical Oncology Unit, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy; University of Milan-Bicocca, Milan, Italy
| |
Collapse
|
11
|
Colombo M, Rizzuto MA, Pacini C, Pandolfi L, Bonizzi A, Truffi M, Monieri M, Catrambone F, Giustra M, Garbujo S, Fiandra L, Corsi F, Prosperi D, Mazzucchelli S. Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer. Bioconjug Chem 2018; 29:3817-3832. [PMID: 30350574 DOI: 10.1021/acs.bioconjchem.8b00667] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The use of therapeutic monoclonal antibodies (mAbs) has revolutionized cancer treatment. The conjugation of mAbs to nanoparticles has been broadly exploited to improve the targeting efficiency of drug nanocarriers taking advantage of high binding efficacy and target selectivity of antibodies for specific cell receptors. However, the therapeutic implications of nanoconjugation have been poorly considered. In this study, half-chain fragments of the anti-EGFR mAb cetuximab were conjugated to colloidal nanoparticles originating stable nanoconjugates that were investigated as surrogates of therapeutic mAbs in triple negative breast cancer (TNBC). Three TNBC cell lines were selected according to EGFR expression, which regulates activation of MAPK/ERK and PI3K/Akt pathways, and to distinctive molecular profiling including KRAS, PTEN, and BRCA1 mutations normally associated with diverse sensitivity to treatment with cetuximab. The molecular mechanisms of action of nanoconjugated half-chain mAb, including cell targeting, interference with downstream signaling pathways, proliferation, cell cycle, and apoptosis, along with triggering of ADCC response, were investigated in detail in sensitive and resistant TNBC cells. We found that half-chain mAb nanoconjugation was able to enhance the therapeutic efficacy and improve the target selectivity against sensitive, but unexpectedly also resistant, TNBC cells. Viability assays and signaling transduction modulation suggested a role of BRCA1 mutation in TNBC resistance to cetuximab alone, whereas its effect could be circumvented using half-chain cetuximab nanoconjugates, suggesting that nanoconjugation not only improved the antibody activity but also exerted different mechanisms of action. Our results provide robust evidence of the potential of half-chain antibody nanoconjugates in the treatment of TNBC, which could offer a new paradigm for therapeutic antibody administration, potentially allowing improved curative efficiency and reduced minimal effective dosages in both sensitive and resistant tumors.
Collapse
Affiliation(s)
- Miriam Colombo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Maria Antonietta Rizzuto
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Chiara Pacini
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Laura Pandolfi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Arianna Bonizzi
- Nanomedicine Laboratory , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy
| | - Marta Truffi
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| | - Matteo Monieri
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| | - Francesco Catrambone
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy.,Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| | - Marco Giustra
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Stefania Garbujo
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Luisa Fiandra
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy.,Nanomedicine Laboratory , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy.,Surgery Department, Breast Unit , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy
| | - Davide Prosperi
- NanoBioLab, Dipartimento di Biotecnologie e Bioscienze , Università di Milano-Bicocca , Piazza della Scienza 2 , 20126 Milano , Italy.,Nanomedicine Laboratory , ICS Maugeri S.p.A. SB , via S. Maugeri 10 , 27100 Pavia , Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "L. Sacco" , University of Milano , via G. B. Grassi 74 , 20157 Milano , Italy
| |
Collapse
|
12
|
Truffi M, Monieri M, Sorrentino L, Mazzucchelli S, Colombo M, Pandolfi L, Prosperi D, Corsi F. Abstract P1-10-11: Multivalent exposure of trastuzumab on iron oxide nanoparticles enhances antitumor activity and weakens drug resistance in HER2+ breast cancer cells. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-10-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The identification of new strategies aimed to optimize the treatment of breast cancer and its metastases represents a great technical and medical challenge. Target-specific therapies, such as Trastuzumab (TZ), have revolutionized the clinical scenario in certain subsets of cancer. However, the huge variability in response to therapy and the frequent onset of drug resistance in patients still hamper the therapeutic success. Antibody-conjugated nanoparticles may combine specific recognition of tumor cells with the capability to act as innovative reservoir of active drugs. Here, multivalent TZ-conjugated colloidal nanoparticles were developed as target-specific and biologically active nanosystem to enhance the therapeutic potential toward HER2+ breast cancer.
Methods: Iron oxide nanoparticles conjugated with multiple half chains of TZ have been developed and tested in different HER2+ breast cancer cell lines, in comparison to free TZ or untargeted nanoparticles. Active targeting and specificity toward HER2 receptor was assessed by flow cytometry and confocal microscopy. Cellular uptake of nanoparticles and HER2 endocytosis were followed by electron or confocal microscopy. Direct anticancer efficacy was assessed by incubation of free or nanoformulated TZ on sensitive breast cancer cells, and analysis of cell viability, cell cycle, and expression of p27kip1. Finally, nanoparticles were tested on TZ-resistant breast cancer cell lines for capability of re-sensitization.
Results: TZ-conjugated nanoparticles showed specific targeting of HER2, with induction of site-specific phosphorylation in the catalytic domain of the receptor and cellular uptake by endocytosis. Treatment with TZ-conjugated nanoparticles dramatically decreased cancer cell viability, by significantly improving the antitumor activity of TZ. This effect was independent from the ADCC mechanism, and associated with marked induction of p27kip1 expression and cell cycle arrest in G1 phase in TZ-sensitive SKBR-3 cells. TZ-conjugated nanoparticles also affected viability of breast cancer cells insensitive to TZ, further confirming enhanced potential of the nanoformulation and suggesting interference with some mechanisms of resistance.
Conclusions: Our results provide evidence that multivalent exposure of TZ half chain on iron oxide nanoparticles affords enhanced antitumor potential and target-specific activity in HER2+ breast cancer cells. Powerful inhibition of HER2 signaling by TZ-conjugated nanoparticles could favor responsiveness of drug resistant cells, thus suggesting novel therapeutic strategies to overcome resistance.
Citation Format: Truffi M, Monieri M, Sorrentino L, Mazzucchelli S, Colombo M, Pandolfi L, Prosperi D, Corsi F. Multivalent exposure of trastuzumab on iron oxide nanoparticles enhances antitumor activity and weakens drug resistance in HER2+ breast cancer cells [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-10-11.
Collapse
Affiliation(s)
- M Truffi
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - M Monieri
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - L Sorrentino
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - S Mazzucchelli
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - M Colombo
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - L Pandolfi
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - D Prosperi
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| | - F Corsi
- University of Milan, "L. Sacco", Milan, Italy; University of Milan-Bicocca, Milan, Italy; ICS Maugeri S.p.A., Pavia, Italy
| |
Collapse
|
13
|
Truffi M, Sorrentino L, Monieri M, Fociani P, Mazzucchelli S, Bonzini M, Zerbi P, Sampietro GM, Di Sabatino A, Corsi F. Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo. Inflamm Bowel Dis 2018; 24:332-345. [PMID: 29361086 DOI: 10.1093/ibd/izx008] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Indexed: 01/13/2023]
Abstract
BACKGROUND Crohn's disease (CD) is a chronic bowel inflammation that ultimately leads to fibrosis, for which medical therapy is currently unavailable. Fibrotic strictures in CD are characterized by excessive extracellular matrix (ECM) deposition, altered balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), and overexpression of fibroblast activation protein (FAP), a marker of active fibroblasts. Here we investigated the role of FAP-targeted therapy in ECM remodeling in CD strictures ex vivo. METHODS Bowel specimens were obtained from stenotic and nonstenotic ileal segments from 30 patients with fibrostenotic CD undergoing surgery. FAP expression was evaluated in isolated mucosal myofibroblasts by immunoblotting and flow cytometry. Bowel tissue cultures were treated with anti-FAP antibody, and soluble collagen, TIMP-1, and MMPs were measured in tissue culture supernatants by immunoblotting. Anti-FAP-treated myofibroblasts were analyzed for TIMP-1 expression by immunoblotting, for migratory potential by wound healing assay, and for apoptosis by Annexin V staining. RESULTS Myofibroblasts from stenotic CD mucosa showed upregulation of FAP expression when compared with nonstenotic mucosa. Treatment of stenotic tissues with anti-FAP antibody induced a dose-dependent decrease in collagen production, particularly affecting type I collagen. The treatment also reduced TIMP-1 production in CD strictures, without altering MMP-3 and MMP-12 secretion. Accordingly, anti-FAP treatment inhibited TIMP-1 expression in stenotic CD myofibroblasts and enhanced myofibroblast migration without affecting survival. CONCLUSIONS FAP inhibition reduced type I collagen and TIMP-1 production by CD strictures ex vivo without compromising uninvolved bowel areas. These results suggest that targeting FAP could reconstitute ECM homeostasis in fibrostenotic CD.
Collapse
Affiliation(s)
- Marta Truffi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy
| | - Luca Sorrentino
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy
| | - Matteo Monieri
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy
| | - Paolo Fociani
- Department of Pathology, IBD Unit, ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy
| | - Matteo Bonzini
- Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Pietro Zerbi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy.,Department of Pathology, IBD Unit, ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy
| | - Gianluca M Sampietro
- Department of Surgery, IBD Unit, ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy
| | - Antonio Di Sabatino
- First Department of Internal Medicine, St. Matteo Hospital Foundation, University of Pavia, Pavia, Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy.,Surgery Department, Breast Unit, ICS Maugeri S.p.A. SBPavia, Italy.,Nanomedicine laboratory, ICS Maugeri S.p.A. SB, Italy, Italy
| |
Collapse
|
14
|
Truffi M, Colombo M, Peñaranda-Avila J, Sorrentino L, Colombo F, Monieri M, Collico V, Zerbi P, Longhi E, Allevi R, Prosperi D, Corsi F. Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. Nanomedicine (Lond) 2017. [PMID: 28621606 DOI: 10.2217/nnm-2017-0004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
AIM We investigate MAdCAM-1 as a reliable target to detect active bowel inflammation for selective noninvasive nanodiagnostics. MATERIALS & METHODS We coupled anti-MAdCAM-1 antibodies to manganese oxide nanoparticles, and analyzed nanoconjugate biodistribution and safety in murine model of inflammatory bowel disease by imaging and histology. RESULTS Nanoparticles were stable and nontoxic. Upon administration in colitic mice, anti-MAdCAM-1 functionalized nanoparticles preferentially localized in the inflamed bowel, whereas untargeted nanoparticles were more rapidly washed out. Nanoparticles did not induce lesions in nontarget organs. CONCLUSION Anti-MAdCAM-1 functionalized nanoparticles detected active bowel inflammation foci, accurately following MAdCAM-1 expression pattern. These nanoconjugates could be a promising noninvasive imaging system for an early and accurate follow-up in patients affected by acute colitis.
Collapse
Affiliation(s)
- Marta Truffi
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy
| | - Miriam Colombo
- Department of Biotechnologies & Biosciences, NanoBioLab, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Jesus Peñaranda-Avila
- Department of Biotechnologies & Biosciences, NanoBioLab, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Luca Sorrentino
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy
| | - Francesco Colombo
- Surgery Department, IBD Unit, ASST Fatebenefratelli Sacco-Luigi Sacco University Hospital, via G. B. Grassi 74, 20157 Milan, Italy
| | - Matteo Monieri
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy
| | - Veronica Collico
- Department of Biotechnologies & Biosciences, NanoBioLab, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Pietro Zerbi
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy.,Pathology Department, ASST Fatebenefratelli Sacco-Luigi Sacco Hospital, via G. B. Grassi 74, 20157 Milan, Italy
| | - Erika Longhi
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy
| | - Raffaele Allevi
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy
| | - Davide Prosperi
- Department of Biotechnologies & Biosciences, NanoBioLab, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Fabio Corsi
- Department of Biomedical & Clinical Sciences 'L. Sacco', University of Milan, via G. B. Grassi 74, 20157 Milan, Italy.,Surgery Department, Breast Unit, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100 Pavia, Italy
| |
Collapse
|
15
|
Truffi M, Fiandra L, Sorrentino L, Monieri M, Corsi F, Mazzucchelli S. Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer. Pharmacol Res 2016; 107:57-65. [DOI: 10.1016/j.phrs.2016.03.002] [Citation(s) in RCA: 141] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Revised: 02/24/2016] [Accepted: 03/02/2016] [Indexed: 12/16/2022]
|